Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 161

1.

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1.

Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJ.

Circulation. 2018 May 7. pii: CIRCULATIONAHA.118.034710. doi: 10.1161/CIRCULATIONAHA.118.034710. [Epub ahead of print]

PMID:
29735484
2.

Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study.

Tamez H, Généreux P, Yeh RW, Amin AP, Fan W, White HD, Kirtane AJ, Stone GW, Gibson CM, Harrington RA, Bhatt DL, Pinto DS; CHAMPION PHOENIX ECONOMICS Investigators.

Catheter Cardiovasc Interv. 2018 May 4. doi: 10.1002/ccd.27638. [Epub ahead of print]

PMID:
29726596
3.

Absence of TetB Identifies Minocycline-Susceptible Isolates of Acinetobacter baumannii.

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson KJ, Thamlikitkul V, Dudley MN, Redell MA.

Int J Antimicrob Agents. 2018 Apr 14. pii: S0924-8579(18)30108-0. doi: 10.1016/j.ijantimicag.2018.04.006. [Epub ahead of print]

PMID:
29665446
4.

Use of an Anti-Infective Medication Review Process at Hospital Discharge to Identify Medication Errors and Optimize Therapy.

Su CP, Hidayat L, Rahman S, Venugopalan V.

J Pharm Pract. 2018 Jan 1:897190018761411. doi: 10.1177/0897190018761411. [Epub ahead of print]

PMID:
29534629
5.

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ.

JAMA. 2018 Feb 27;319(8):788-799. doi: 10.1001/jama.2018.0438.

PMID:
29486041
6.

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02228-17. doi: 10.1128/AAC.02228-17. Print 2018 Apr.

PMID:
29437614
7.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.

Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W; SOLO I and SOLO II investigators.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01919-17. doi: 10.1128/AAC.01919-17. Print 2018 Apr.

PMID:
29358292
8.

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.

Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02103-17. doi: 10.1128/AAC.02103-17. Print 2018 Mar.

PMID:
29311069
9.

Early clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial.

Huber K, Ducrocq G, Hamm CW, van 't Hof A, Lapostolle F, Coste P, Gordini G, Steinmetz J, Verheugt FWA, Adgey J, Nibbe L, Kaniĉ V, Clemmensen P, Zeymer U, Bernstein D, Prats J, Deliargyris EN, Gabriel Steg P.

Open Heart. 2017 Nov 28;4(2):e000677. doi: 10.1136/openhrt-2017-000677. eCollection 2017.

10.

30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.

Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF.

Antimicrob Resist Infect Control. 2017 Dec 6;6:124. doi: 10.1186/s13756-017-0286-9. eCollection 2017.

11.

Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.

Qaderdan K, Vos GA, McAndrew T, Steg PG, Hamm CW, Van't Hof A, Mehran R, Deliargyris EN, Bernstein D, Stone GW, Ten Berg JM.

Am Heart J. 2017 Dec;194:73-82. doi: 10.1016/j.ahj.2017.08.009. Epub 2017 Aug 18.

PMID:
29223437
12.

Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.

Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01969-17. doi: 10.1128/AAC.01969-17. Print 2018 Feb.

PMID:
29133570
13.

Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection.

Trang M, Dudley MN, Bhavnani SM.

Curr Opin Pharmacol. 2017 Oct;36:107-113. doi: 10.1016/j.coph.2017.09.009. Epub 2017 Nov 10. Review.

PMID:
29128853
14.

Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Belley A, Arhin FF, Moeck G.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01873-17. doi: 10.1128/AAC.01873-17. Print 2018 Jan.

PMID:
29109163
15.

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.

Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01446-17. doi: 10.1128/AAC.01446-17. Print 2018 Jan.

PMID:
29109160
16.

β-Lactamase inhibitors: what you really need to know.

Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B.

Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Review.

PMID:
29096172
17.

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.

Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17. doi: 10.1128/AAC.01904-17. Print 2018 Jan.

18.

Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.

Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J.

JAMA Cardiol. 2018 Feb 1;3(2):164-168. doi: 10.1001/jamacardio.2017.3833.

PMID:
29071331
19.

P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease.

Kaza EA, Egalka MC, Zhou H, Chen J, Evans D, Prats J, Li R, Diamond SL, Vincent JA, Bacha EA, Diacovo TG.

JACC Basic Transl Sci. 2017 Aug;2(4):465-476. doi: 10.1016/j.jacbts.2017.04.002. Epub 2017 Jul 19.

20.

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.

Weiss WJ, Pulse ME, Nguyen P, Peterson K, Silva J, Simecka JW, Valtierra D, Sabet M, Griffith DC.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01439-17. doi: 10.1128/AAC.01439-17. Print 2018 Jan.

PMID:
29038270

Supplemental Content

Loading ...
Support Center